insights_auto
Why is DUL up 5.20%?
Dive Deeperchevron_right
DUL:ETR
Alnylam Pharmaceuticals, Inc.
€206.50
arrow_upward
+5.20%(+10.20) 1D
Oct 9, 5:35:58 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DUL...
Open
€200.20
High
€206.50
Low
€200.10
Mkt. cap
31.13B
Avg. vol.
40.00
Volume
0.00
52-wk high
€417.40
52-wk low
€177.10
No. of employees
2K
Open
€200.20
High
€206.50
Low
€200.10
Mkt. cap
31.13B
Avg. vol.
40.00
Volume
0.00
52-wk high
€417.40
52-wk low
€177.10
No. of employees
2K
News stories
From web sources and news partners
Investing.com
·
15 hours ago
Alnylam EVP Bryan Supran sells $398,855 in shares
Investing.com Nigeria
·
15 hours ago
Form 4 Alnylam Pharmaceuticals Inc For: 11 October By Investing.com
Simply Wall Street
·
16 hours ago
How Securities Fraud Scrutiny Will Impact Alnylam Stock Investors
The Motley Fool
·
1 day ago
Alnylam vs. Ionis: Here's the Better Bad-News Buy
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.